Analysts at StockNews.com began coverage on shares of FibroGen (NASDAQ:FGEN – Get Free Report) in a research report issued to clients and investors on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.
FibroGen Trading Down 0.9 %
FGEN stock opened at $0.39 on Monday. The firm has a market cap of $38.94 million, a PE ratio of -0.16 and a beta of 0.70. FibroGen has a 1 year low of $0.30 and a 1 year high of $2.93. The company has a fifty day simple moving average of $0.39 and a 200 day simple moving average of $0.84.
FibroGen (NASDAQ:FGEN – Get Free Report) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.09. The business had revenue of $50.64 million for the quarter, compared to analyst estimates of $33.00 million. During the same period in the previous year, the company earned ($0.65) earnings per share. As a group, analysts forecast that FibroGen will post -0.91 EPS for the current fiscal year.
Hedge Funds Weigh In On FibroGen
FibroGen Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
See Also
- Five stocks we like better than FibroGen
- Stock Splits, Do They Really Impact Investors?
- Is Spotify Stock Poised to Soar? Options Traders Think So
- What is a Dividend King?
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- 3 Warren Buffett Stocks to Buy Now
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.